Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

European Medicines Agency Supports Streamlined Development Pathway for GEO-MVA Vaccine Candidate via a Single Phase 3 ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research ...

ATLANTA, GA - June 25, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, ...

Detailed price information for Geovax Labs (GOVX-Q) from The Globe and Mail including charting and trades.

--GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued a ...

GeoVax has other ongoing Phase 2 trials assessing GEO-CM04S1 as a primary vaccine for immunocompromised patients and as a durable booster for individuals previously vaccinated with mRNA vaccines.

If you are interested in arranging a 1x1 meeting request with management, please contact your ROTH representative, or please contact the company directly at [email protected]. GeoVax Labs, Inc. is a ...

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers.

GeoVax entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 1.7 million shares of its common stock for $5 per share in a ...